Syntekabio’s Pipeline Story
Drug Discovery: Humanity’s Long-standing Challenge.
Drug discovery has always been one of humanity’s greatest challenges.
Traditional approaches require enormous time and cost, yet deliver a success rate of barely 10%.
This inefficiency is now being disrupted by AI-driven drug discovery.
Syntekabio is building a new pipeline powered by AI,
enabling projects that were once out of reach with conventional methods.
In this article, we explore the present and future of AI-driven drug discovery
—and how Syntekabio is shaping this transformation.
One-Click Drug Discovery Process
One of Syntekabio’s core concepts is the “One-Click Pipeline.”
This refers to a seamless flow where each stage is executed with a single click, leading to the next with equal simplicity.
First Click: Hit identification → Validation by global CROs
Second Click: Efficacy optimization → Validation by global CROs
Third Click: ADME-Tox (absorption, distribution, metabolism, excretion, toxicity) evaluation → Validation by global CROs
By combining computing power, cloud infrastructure, and AI algorithms,
Syntekabio can simultaneously explore and validate multiple disease targets.
The Strengths of AI Beyond Traditional Drug Discovery
AI-driven drug discovery is not simply about speed—it offers innovative advantages that can fundamentally replace traditional approaches.
1. Dramatically Expanded Search Space
– Traditional methods stalled at thousands of compounds, while AI can simulate billions of molecules.
2. Theory-Based Exploration
– Instead of intuition and trial-and-error, AI leverages physics and chemistry principles to understand protein–compound interactions.
3. Parallel Project Execution
– With sufficient computing resources, dozens of projects can run simultaneously in parallel.
4. Cost Efficiency
– Initial exploration can be conducted at the cost of running supercomputers, rather than relying on expensive laboratory experiments.
In short, AI brings speed, lower cost, and higher success rates—this is its true value.
Syntekabio’s Readiness: Vast Target Data
The starting point of AI drug discovery is protein structural information.
In the past, only about 30% of human protein structures had been identified, which posed significant limitations.
With the advent of AI prediction models such as AlphaFold2 and ESMFold, accessibility has greatly improved.
Syntekabio has already built 1,491 genes and 3,518 protein models.
These include proteins associated with more than 500 diseases
—covering over 80% of cancer-related proteins among 110 known cancer types.
In other words, Syntekabio is “ready to simulate drug discovery for diverse diseases at any time.”
Drug Repurposing: Discovering New Potential from Existing Drugs
Drug discovery does not only mean developing entirely new drugs.
Drug repurposing—applying already approved drugs to new indications—is an equally important strategy.
Syntekabio applied more than 3,000 existing drugs to 500 protein models, identifying 437 valid combinations.
Among these, 58 candidates showed significant efficacy in experiments and are now being advanced to animal studies.
This process not only broadened candidate discovery but also reinforced the credibility and performance of Syntekabio’s AI platform.
Candidate Optimization: The Crossroads of Drug Development Success
Many drug candidates fail in clinical trials due to insufficient optimization.
Even if effective, compounds with strong toxicity or poor metabolic properties ultimately cannot reach the market.
To overcome this, Syntekabio has developed an Auto-Lead-Optimization platform.
This system automatically modifies and improves candidate molecules, enhancing binding affinity, reducing toxicity, and supporting patent novelty.
Thus, the process goes beyond discovery—raising the likelihood of clinical success.
The Future of AI Drug Discovery and Syntekabio’s Role
AI is now transforming the entire drug development lifecycle
—from candidate discovery to preclinical toxicity assessment, clinical trial design, and even patient recruitment optimization.
Industry consensus is growing that AI will become the new standard in drug development.
For example, Insilico Medicine’s AI-designed drug candidate receiving FDA Orphan Drug Designation is a landmark case highlighting this change.
Amid this shift, Syntekabio is taking the lead with three core pillars:
Large-scale validation
Platform advancement
Parallel project execution
✅ In summary,
AI drug discovery is faster, more efficient, and more successful.
Syntekabio has secured vast target data and advanced optimization platforms.
In the future, AI will no longer be optional in drug discovery—it will be indispensable.
AI-driven drug discovery is no longer a future possibility—it is a present reality.
And Syntekabio stands at the center of this transformation.
🔗 Open Link
[Feature] Syntekabio Draws the Future of “AI Drug Discovery Pipeline & Drug Repurposing” <4>
